Technavio, a US-based global technology research and advisory company, announced on Thursday that the global autism spectrum disorder (ASD) therapeutics market size is expected to increase by USD766.1m from 2024 to 2028.

The market is likely to increase at a CAGR of 6.78% during the forecast period.

Increasing prevalence of asd is driving market growth, with a trend towards increasing interest in personalized medicine for treatment of ASD.

The main market players include ASSERTIO HOLDINGS INC., AutismSTEP, Bristol Myers Squibb Co., CureMark LLC, F. Hoffmann La Roche Ltd., Fraser, Jazz Pharmaceuticals Plc, Johnson and Johnson Services Inc., Les Laboratoires Servier, Neurim Pharmaceuticals Ltd., Novartis AG, Oryzon Genomics SA, Otsuka Holdings Co. Ltd., PaxMedica Inc., Q BioMed Inc., Scioto Biosciences Inc., Stalicla SA, Travere Therapeutics Inc., Yamo Pharmaceuticals LLC and Zynerba Pharmaceuticals Inc.